Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mesa Labs (MLAB) came out with quarterly earnings of $2.32 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.83 per share a year ago.
Mesa Labs (MLAB) came out with quarterly earnings of $2.23 per share, missing the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $2.77 per share a year ago.
| Automobile Components Industry | Consumer Discretionary Sector | Gary Owens CEO | XMUN Exchange | US59064R1095 ISIN |
| US Country | 741 Employees | 31 Aug 2026 Last Dividend | - Last Split | 25 Jan 1995 IPO Date |
Mesa Laboratories, Inc. is a prominent player in the life sciences industry, focusing on the development, manufacturing, and sale of tools and quality control products and services. The company's operations span across North America, Europe, the Asia Pacific, and other international markets, catering to the diverse needs of the clinical genomics, sterilization and disinfection control, biopharmaceutical development, and calibration solutions sectors. Founded in 1982, Mesa Laboratories, Inc. has established itself as a pivotal entity, providing innovative solutions in various therapeutic areas including hereditary disease screenings, pharmacogenetics, oncology applications, and more. The company's unique positioning and extensive product range allow it to serve a wide array of industries including hospitals, dental, medical device, and pharmaceutical industries.